

Assistant Commissioner
for Patents
Washington, D.C. 20231

**AMENDMENT AND REQUEST FOR
RECONSIDERATION UNDER 37 C.F.R. §1.111**

Dear Sir:

In response to the Official Action dated October 2, 2001, reconsideration of the Restriction Requirement and the rejection of claims 1-12, 16, 17, 19, and 27-32 of the above-identified patent application is respectfully requested in light of the following amendments and remarks:

In the Specification:

Please delete the four consecutive paragraphs beginning on page 5 at line 28 and ending on page 6 at line 23. Please substitute the following replacement paragraphs therefor:

C1
--Accordingly, in a further aspect, the present invention provides a cancer vaccine comprising 791Tgp72 antigen or a polypeptide of the CD55 family, or a fragment or derivative of 791Tgp72 or of a polypeptide of the CD55 family, wherein the vaccine is capable of inducing an immune response in a patient. The response may be one or more of a T-helper cell response, a cytotoxic T-cell response, an NK cell response and/or an immune response.

In a further aspect, the present invention provides a cancer vaccine comprising nucleic acid encoding 791Tgp72 and/or a polypeptide of the CD55 family, or a fragment or derivative of 791Tgp72 or of a polypeptide of the CD55 family, wherein the

#11/c
JW
4/30/02